22
Participants
Start Date
May 26, 2023
Primary Completion Date
June 24, 2026
Study Completion Date
March 31, 2027
Daratumumab
Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Daratumumab
Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Daratumumab
Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
RECRUITING
NYU Langone, New York
RECRUITING
Hospital for Special Surgery, New York
RECRUITING
Weill Cornell, New York
RECRUITING
Northwell Health, Great Neck
RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
Duke University, Durham
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Mayo Clinic Rochester, Rochester
Collaborators (1)
Immune Tolerance Network (ITN)
NETWORK
PPD Development, LP
INDUSTRY
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH